Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR SymposiumGlobeNewsWire • Wednesday
Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 StudyGlobeNewsWire • 09/25/24
Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewsWire • 09/04/24
Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting LetterGlobeNewsWire • 09/03/24
Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical CompositionsGlobeNewsWire • 06/26/24
Cyclacel's Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual MeetingGlobeNewsWire • 06/04/24
Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ RulesGlobeNewsWire • 05/02/24
Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq RulesGlobeNewsWire • 04/30/24
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for CancerGlobeNewsWire • 04/01/24
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 03/19/24
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewsWire • 03/13/24
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024GlobeNewsWire • 03/07/24
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor ConferenceGlobeNewsWire • 02/20/24
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical OfficerGlobeNewsWire • 01/30/24
Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price RequirementGlobeNewsWire • 01/08/24
Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq RulesGlobeNewsWire • 12/22/23